Outcomes after standard chemotherapy or epigenetic therapy in patients with poor- and intermediate-risk cytogenetics
| . | Chemotherapy . | Epigenetic . | P . |
|---|---|---|---|
| Poor-risk CG patients, n (%) | 187 (83%) | 38 (17%) | |
| Outcome | |||
| ORR | 61 (33%) | 10 (26%) | .447 |
| CR | 52 (28%) | 10 (26%) | .849 |
| CRp | 9 (5%) | 0 (0%) | NR |
| No response | 78 (42%) | 19 (0%) | NR |
| ED < 8 wk | 46 (25%) | 6 (16%) | .242 |
| Median OS, mo | 3.2 | 4.2 | .315 |
| 1-y | 17% | 26% | |
| 2-y | 7% | 11% | |
| Median RFS, mo | 9.3 | 10.5 | .104 |
| 1-y | 42% | 46% | |
| 2-y | 8% | 46% | |
| Intermediate-risk CG patients, n (%) | 350 (81%) | 71 (19%) | |
| Outcome | |||
| ORR | 194 (55%) | 23 (32%) | .0006 |
| CR | 176 (50%) | 22 (31%) | < .001 |
| CRp | 18 (5%) | 1 (1%) | NR |
| No response | 105 (30%) | 41 (58%) | NR |
| ED < 8 wk | 50 (14%) | 6 (8%) | .187 |
| Median OS, mo | 9.5 | 8.8 | .134 |
| 1-y | 43% | 34% | |
| 2-y | 24% | 12% | |
| Median RFS, mo | 13 | 9.5 | .673 |
| 1-y | 53% | 46% | |
| 2-y | 35% | 37% | |
| . | Chemotherapy . | Epigenetic . | P . |
|---|---|---|---|
| Poor-risk CG patients, n (%) | 187 (83%) | 38 (17%) | |
| Outcome | |||
| ORR | 61 (33%) | 10 (26%) | .447 |
| CR | 52 (28%) | 10 (26%) | .849 |
| CRp | 9 (5%) | 0 (0%) | NR |
| No response | 78 (42%) | 19 (0%) | NR |
| ED < 8 wk | 46 (25%) | 6 (16%) | .242 |
| Median OS, mo | 3.2 | 4.2 | .315 |
| 1-y | 17% | 26% | |
| 2-y | 7% | 11% | |
| Median RFS, mo | 9.3 | 10.5 | .104 |
| 1-y | 42% | 46% | |
| 2-y | 8% | 46% | |
| Intermediate-risk CG patients, n (%) | 350 (81%) | 71 (19%) | |
| Outcome | |||
| ORR | 194 (55%) | 23 (32%) | .0006 |
| CR | 176 (50%) | 22 (31%) | < .001 |
| CRp | 18 (5%) | 1 (1%) | NR |
| No response | 105 (30%) | 41 (58%) | NR |
| ED < 8 wk | 50 (14%) | 6 (8%) | .187 |
| Median OS, mo | 9.5 | 8.8 | .134 |
| 1-y | 43% | 34% | |
| 2-y | 24% | 12% | |
| Median RFS, mo | 13 | 9.5 | .673 |
| 1-y | 53% | 46% | |
| 2-y | 35% | 37% | |
CRp indicates CR with incomplete platelet recovery; ED, early death; RFS, relapse-free survival; CG, cytogenetics; and NR, not reported.